Audit: QRS - Chrysin to Treat Cancer

Audit conducted on 22/09/2026 16:43 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells against ER Therapeutic Protocol / Discontinuation & Cycling / Practical Considerations, benefits and risks against the tiered ER headings, gates against Key Interactions & Contraindications, markers and cadence against Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“That bowel-directed question stays open rather than answered” mirrors the ER Conclusion; “About 1 week” keeps the ER’s “about”; speculative tiers carry the ER’s own tier label.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy and lactation” stays a contraindication; the absent High/Medium tiers are hidden rather than promoted; no benefit is upgraded past the ER’s tier.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid Chrysin” list; interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor is carried into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names appear anywhere in the QRS; the ER’s “Kamal Patel”, “Tobin”, “Isura” and “Sabinsa” attributions were correctly dropped.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS body.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s flat, sceptical register throughout (“stays open rather than answered”, “no systemic effect appears at any interval”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Technical terms are used where the ER uses them, with plain-language framing in the lede; tiers and targets give the reader concrete handles.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring content is stated descriptively (“Dose identified as sufficient for bowel-local purposes”), not as instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; the footer disclaimer is the template’s unchanged text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or “we suggest” in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the QRS.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	The lede is jargon-free; the technical terms that remain (BCRP, UGT1A1, CYP1A1, PD-L1) are the ER’s own and are load-bearing identifiers in the gates and tiers.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and risks are collapsed to one semicolon-separated line per tier; gate items carry the key fact only.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address anywhere on the sheet.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker targets, genetic-variant-aware interaction list and the absorption-ceiling framing all address the proactive reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, 24-hour separations from infusion, and a nine-marker monitoring panel are presented without hedging on inconvenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification down to general-population level; functional rather than conventional lab ranges are used.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede leads with the absorption failure and the narrow bowel-local case, which is the decision-relevant signal for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not appear in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“oral doses”, “daily supplementation”, “mild adverse events”, “hepatic impairment” — no colloquial substitutes; the lede says “oral doses barely enter the blood”, not “taken by mouth”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings match the template byte-for-byte (lines 446, 492, 543, 569, 585, 616, 640, 644–646, 787); the “Low: “ and “Speculative: “ tier labels are intact, and the unused High/Medium spans are hidden per 12.5/13.5.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Diff of the extracted variable names against the template shows no template variable missing; the only extras are the legitimate expansions of the repeatable marker_#_* and qualitative_item_# rows.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans and the footer disclaimer are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section that feeds the QRS is empty; the absent High/Medium tiers are governed by 12.5/13.5, not by empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Colon-targeted low dose”, “Single versus split dosing”, “Best time of day”, “Time to effect”, “Intended duration”, “Half-life” are all the ER’s own bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Every protocol and time label is a verbatim ER bullet label; no invented labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Unicode scan for emoji ranges returns nothing; the ER’s ⭕️ and ⚠️ flags were dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Condensation is visible throughout: 12 ER protocol bullets reduced to 3 cells, tiered benefits and risks collapsed to one line per tier, contraindication and interaction rationales stripped.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no duplicate of the values appears in the rendered body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, which the embedded colon requires; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: chrysin_cancer_2026-0921-0324_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.22, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0922-1639.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: chrysin_cancer_2026-0921-0324_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; consistent and clean.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Chrysin to Treat Cancer - Quick Reference Sheet”; no characters requiring entity encoding.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Chrysin to Treat Cancer”, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/22/2026” from qrs_creation_date: 2026-0922-1639.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block is structurally identical to the template; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Chrysin is a dietary supplement made from a plant compound in honey, bee propolis and passionflower, sold to people facing cancer” — kind and use stated before any verdict.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Each sentence maps to a Conclusion paragraph: laboratory-versus-human gap, conjugation and return to the bowel, the open bowel-directed question.
7.3	[at_a_glance] is no longer than 70 words	🟢	68 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Sources are ER Conclusion paragraphs 1–3 plus the Motivation line on supplement marketing to people facing cancer.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “laboratory dishes”, “gut enzymes” and “bowel” replace in vitro, conjugating enzymes and colon.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial named, no year, no sample size.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind in the lede.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items come from that section’s “Populations who should avoid Chrysin” sub-list (ER lines 309–314).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoid-populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the span (lines 572–580).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing “where …” / “given …” / “for whom …” rationales were stripped from all four items that carried them.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“below 1.5 × 10⁹/L”, “within 7 days of an irinotecan or topotecan infusion”, “Child-Pugh Class B or C” and “under 18” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the ER’s seven interaction bullets (ER lines 293–305).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All seven ER interactions present; no overlap with the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements inside the span (lines 588–606).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “caution/monitor” verdict, mechanism sentence and “Mitigation:” clause was stripped; the em-dash gloss on pembrolizumab in the ER’s last bullet was correctly removed.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All seven parenthetical drug and supplement lists are preserved intact.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s parentheticals are already plain comma-separated lists with no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names seven interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol bullets (ER lines 334–342).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, dosing frequency and timing — the three decisions a reader must make; the absorption ceiling from the “Standard oral dose” bullet is folded into the dose cell’s sub.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies twelve protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Onset (ER Practical Considerations), intended duration (ER Discontinuation & Cycling) and half-life (ER Therapeutic Protocol / Mechanism of Action).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Onset of gut-enzyme induction — the mechanism behind the ER’s leading Low-tier benefit — comes first, then duration, then the pharmacokinetic half-life.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist in the ER; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; subs are near-verbatim ER sentences.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides an explicit “Time to effect” bullet, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine listed benefits map to ER Expected Benefits headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present (lines 545, 546, 547, 554).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER heading reduced to lower case; all Magnitude: lines (59% tumour reduction, 3–16 ng/mL, 5.2→4.2 mmol/L) are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in either benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High and no Medium benefit; both spans are emptied and carry style="display: none".

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight listed risks map to ER Low and Speculative headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present (lines 618, 619, 620, 628).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Grade 3/4 neutropenia rates, the 103%/86% estradiol rises and the 8.6% patch-test figure are all stripped; the ER’s ⚠️ Conflicted flag is dropped per 4.4.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in either risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High and no Medium risk; both spans are emptied and carry style="display: none".

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table and cadence both trace to ER Monitoring Protocol & Defining Success.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarker rows present in order — ALT, AST, total bilirubin, eGFR, absolute neutrophil count, estradiol, total testosterone, hs-CRP, CEA — with targets and “Why Measure It?” text carried verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 777: baseline / 4 weeks / 12 weeks / every 3–6 months, hormones at 8 weeks then every 6 months, counts before each chemotherapy cycle — matching ER lines 413–415.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the ER’s “Qualitative markers tracked alongside the laboratory values” list (ER lines 431–435).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers present and verbatim.

Issues 22/09/2026 16:43

Pass rate 100.00%. No issues found.